Clinical Trials Logo

Metabolic Syndrome clinical trials

View clinical trials related to Metabolic Syndrome.

Filter by:

NCT ID: NCT01176942 Completed - Metabolic Syndrome Clinical Trials

Probiotics and Endotoxemia

PROMS-01
Start date: May 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether probiotic treatment of overweight volunteers consuming high fat diet is able to reduce plasma lipopolysaccharide concentration.

NCT ID: NCT01176630 Completed - Metabolic Syndrome Clinical Trials

Prevalence of Metabolic Syndrome in a Maintenance Hemodialysis Population

Start date: August 2010
Phase: N/A
Study type: Observational

The study is a survey to answer the specific question, "What is the prevalence of metabolic syndrome in maintenance hemodialysis patients?" Metabolic syndrome is a cluster of conditions that increase an individual's risk for developing cardiovascular disease and diabetes.

NCT ID: NCT01173432 Completed - Metabolic Syndrome Clinical Trials

Exploring the Role of Adipocyte Fatty Acid Binding Protein in the Association of Obstructive Sleep Apnea and Metabolic Dysfunction

Start date: June 2008
Phase: N/A
Study type: Interventional

Adipocyte fatty acid binding protein (A-FABP) is a member of the FABP super family, is abundant in adipocytes and macrophages. Regulatory functions of A-FABP in lipid and glucose metabolism have been described, and it is suggested to play an important role in the pathogenesis of metabolic syndrome.We hypothesize that obstructive sleep apnea (OSA) may upregulate A-FABP production and thus causally contribute to metabolic dysfunction. Our group has recently demonstrated that A-FABP, expressed and secreted from adipocytes, is present in the blood stream .The levels of A-FABP correlated with various metabolic variates in the metabolic syndrome. Furthermore, we have obtained novel data in men with a range of sleep disordered breathing showed that the duration of oxygen desaturation correlated with circulating levels of A-FABP, independent of age and waist/body mass index. The current proposal aims to pursue this finding and further explore the role of A-FABP in the association of OSA and metabolic dysfunction.

NCT ID: NCT01165853 Completed - Metabolic Syndrome Clinical Trials

Effects of Consuming Sugar-Sweetened Beverages With Meals for 10 Weeks

IPOP
Start date: July 2005
Phase: N/A
Study type: Interventional

The purpose of this study is compare the effects of consuming glucose- and fructose-sweetened beverages on appetite, body weight, body fat, and the amount of energy the body burns as well as effects on blood pressure, hormones, blood triglycerides and cholesterol, and the body's sensitivity to the insulin.

NCT ID: NCT01154478 Completed - Metabolic Syndrome Clinical Trials

Effects of Dietary Polyphenols and ω-3 Fatty Acids on Cardiovascular Risk Factors in High Risk Subjects

Etherpaths
Start date: January 2010
Phase: N/A
Study type: Interventional

The aim of this study is to explore if a 8-weeks dietary intervention with polyphenols and omega 3 fatty acids (alone or combined) may be effective on postprandial lipids metabolism and other cardiovascular risk factors in people at high cardiovascular risk.

NCT ID: NCT01150981 Completed - Metabolic Syndrome Clinical Trials

Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue

RAPA
Start date: November 2006
Phase: Phase 2
Study type: Interventional

Insulin resistance is a common condition that can lead to type 2 diabetes. One of the commonly prescribed diabetes medications, called rosiglitazone, works by decreasing insulin resistance. Rosiglitazone appears to work on fat cells. Animal studies suggest that rosiglitazone may work by increasing blood vessel growth in fat cells. The purpose of this research is to see if rosiglitazone also increases blood vessel growth in human fat cells. The investigators will compare results from before and after being on rosiglitazone for 6 weeks.

NCT ID: NCT01150955 Completed - Obesity Clinical Trials

Potential Beneficial Effects of Resveratrol

Start date: October 2010
Phase: N/A
Study type: Interventional

We want to investigate whether the food supplement resveratrol is able to counteract the detrimental effects of obesity.

NCT ID: NCT01146314 Completed - Type 2 Diabetes Clinical Trials

A Family Based Intervention to Reduce the Risk of Type 2 Diabetes in Children

FBI
Start date: September 2006
Phase: N/A
Study type: Interventional

The purpose of this study was to determine if a family-focused lifestyle intervention helps to improve the health status, behaviors, and adjustment of overweight children.

NCT ID: NCT01145066 Completed - Diabetes Clinical Trials

Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects

Start date: May 2009
Phase: Phase 2
Study type: Interventional

This study will compare how well a combination of borage and echium oils will reduce inflammation compared to fish oils and placebo oil in subjects that are diabetic or have metabolic syndrome.

NCT ID: NCT01138423 Completed - Hypertension Clinical Trials

Treatment of Adiposity Related hypErTension (TARGET)

TARGET
Start date: August 2010
Phase: Phase 4
Study type: Interventional

High blood pressure (hypertension) is an important cause of myocardial infarction and stroke. High blood pressure often occurs in people who are overweight. These people frequently also have abnormal fat and sugar metabolism. The combination of these problems is called the 'metabolic syndrome'. People with hypertension and obesity currently receive the same drug therapy as people with hypertension, but without obesity. Different classes of drugs are thought to be equally effective in lowering blood pressure. Next to lowering blood pressure, hypertension treatment can have additional effects, like changes in blood vessel function (the ability to dilate and constrict) or changes is the metabolism of sugar and fat. Particularly in patients with the metabolic syndrome, these additional effects are thought to be of great importance, because they can influence the risk for cardiovascular diseases. The blood pressure lowering mechanism differs between classes of blood pressure lowering medication. The purpose of this study is to compare the effects of three types of blood pressure lowering medication belonging to different classes. The main outcomes of interest will be blood vessel function (the ability to dilate and constrict) and blood pressure. Moreover, the effect of treatment on additional outcomes, like metabolism of sugar and fat, will be studied.